ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro reported Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, driven by the IRRAflow acquisition and increased disposables sales, though the net loss widened to $11.3 million.
The company adjusted its full-year 2026 revenue guidance to $48.0 million to $52.0 million to prioritize investment in clinical capacity and preclinical services at the new ClearPoint Advanced Laboratories facility rather than traditional sales expansion.
Strategic highlights include a 10-year focused ultrasound partnership with SONOCARE Lab and positive regulatory feedback from biopharma partners, with 10-15 clinical trials expected to enroll in the next 18 months.